Maotai Group went to Laos, Cambodia and Thailand for investigation and exchange. From December 3 to 9, local time, Wan Bo, member of the Party Committee and deputy general manager of Maotai Group, led a team to Laos, Cambodia and Thailand for investigation and exchange. Through in-depth investigation of the local market, the brand promotion activities of "Maotai Night" were carried out, which continued to promote Maotai's deep cultivation in Southeast Asia. During this period, Wanbo and his party also visited Eisenwo, Chairman of the China-Cambodia Friendship Exchange Association, Princess Norodom Allen Rasmi, Director of the Cambodian Royal Modita Foundation, former Thai Deputy Prime Minister Chichai Vanashati, Chairman of the Thailand-China Friendship Association and former Thai Deputy Prime Minister Gong Taparansi, and Lao Minister of Education and Sports Pu Simarong to discuss how Maotai culture and Southeast Asian cultures can be blended and promoted together to help Maotai and China traditional culture go to sea.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.
In 2024, the number of cases of dengue fever in Brazil exceeded 6.76 million. On December 10, local time, according to the latest data from the Brazilian Ministry of Health, this year, the number of suspected and confirmed cases of dengue fever in Brazil rose to 6,763,743, and the number of deaths rose to 5,950, with another 1,091 deaths to be verified. In 2024, the number of cases of dengue fever infection in Brazil reached a record high since the country's epidemic record, which was three times that of 2023. The death toll of dengue fever has also reached a record high, four times that of 2023. The regions with the highest infection rates are federal capital territory, minas gerais, Balana and Sã o Paulo.Sagitar Juchuang will raise HK$ 277.5 million by placing shares. According to the announcement of the Hong Kong Stock Exchange, the robotics company Sagitar Juchuang agreed to place 10 million new shares at a price of HK$ 27.75 per share. The matching price is about 8% lower than Tuesday's closing price of HK$ 30.15 per share. The proceeds from the placement of shares will be mainly used for research and development, enhancing business development capabilities in overseas markets and exploring potential strategic partnership or alliance opportunities.The negotiation between Myriad and United Health Insurance may be extended to the beginning of 2025, and the negotiation between Myriad Genetics and UnitedHealthcare on the genetic test of Myriad may continue until the beginning of 2025. Myriad reiterated its estimate of the financial impact of the United Health Insurance Company's updated medical policy in 2024.
Maotai Group went to Laos, Cambodia and Thailand for investigation and exchange. From December 3 to 9, local time, Wan Bo, member of the Party Committee and deputy general manager of Maotai Group, led a team to Laos, Cambodia and Thailand for investigation and exchange. Through in-depth investigation of the local market, the brand promotion activities of "Maotai Night" were carried out, which continued to promote Maotai's deep cultivation in Southeast Asia. During this period, Wanbo and his party also visited Eisenwo, Chairman of the China-Cambodia Friendship Exchange Association, Princess Norodom Allen Rasmi, Director of the Cambodian Royal Modita Foundation, former Thai Deputy Prime Minister Chichai Vanashati, Chairman of the Thailand-China Friendship Association and former Thai Deputy Prime Minister Gong Taparansi, and Lao Minister of Education and Sports Pu Simarong to discuss how Maotai culture and Southeast Asian cultures can be blended and promoted together to help Maotai and China traditional culture go to sea.South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.